Quality of Life and Clinical Outcomes in Patients Treated With Leadless Micra Transcatheter Pacemakers as Compared With Traditional Transvenous Pacemakers

Shanghai Zhongshan Hospital0 sites246 target enrollmentJuly 2023

ConditionsLeadless Micra Transcatheter Pacemaker Quality of Life

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Leadless Micra Transcatheter Pacemaker
Sponsor: Shanghai Zhongshan Hospital
Enrollment: 246
Primary Endpoint: Health-related quality of life measured by NHP (Nottingham Health Profile)
Status: Not yet recruiting
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

The study aims to carry out a domestic multi-center, prospective, non-randomized, non-blinded post-approval study to assess health-related QoL between Micra TPS and conventional PM implantation. Meanwhile, pocket and leads related complications would also be evaluated between these two strategies.

Registry

clinicaltrials.gov

Start Date

July 2023

End Date

June 2026

Last Updated

2 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Shanghai Zhongshan Hospital

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•With an age arranged from 18 to 80 years old;
•Conforming to indication of a pacemaker implantation;
•Life expectancy\>1 year;
•Normal cardiac function with preserved LVEF;
•Adequate self-care ability or self-help skills before pacemaker implantation;
•Mentally healthy so as to participate in the quality-of-life assessments;
•Willing to participate in study through consent and willing to undergo study specific required procedures with expectancy of geographically stable for follow up duration.

Exclusion Criteria

•Subject with indication for ICD/ CRT-P/CRT-D;
•Subject with persistent symptomatic sinus bradycardia;
•Subject has an existing or prior pacemaker, ICD or CRT device implant;
•Subject has unstable angina pectoris or has an acute myocardial infarction (AMI) in the 30 days prior to eligibility assessment;
•Subjects with a mechanical tricuspid valve, implanted vena cava filter, or left ventricular assist device (LVAD);
•Subjects with a life expectancy of less than 12-months;
•Subjects with medical condition which precludes patient from participation in the opinion of the investigator, such as arthritis, lung disease or previous stroke, renal dysfunction, recent major surgery within six months, clinically overt congestive heart failure;
•Pregnant women or breastfeeding women, or women of child bearing potential and who are not on a reliable form of birth regulation method or abstinence;
•Psychological disorders unable to participate in the quality-of-life assessments.